In January, Yowie Group Ltd (ASX: YOW) posted a positive announcement regarding Nielsen scan data results for its ‘front end’ (i.e., on store shelves) sales performance for the 13 weeks to December 26, 2015.

At the time, Yowie was the #1 Novelty candy item, and #8 overall top-selling front end candy item. It was also the sixth most popular convenience store item, despite tiny distribution. Yowie today announced an update for front-end sales performance for the 52 weeks to 26 March, 2016, and the results have beaten the company’s previous achievements.

Yowie is the:

  • #1 selling novelty candy item in the US market for the 52 weeks to 26 March 2016
  • #3 selling item in total US candy market for the 52 weeks to 26 March 2016
  • #1 selling item in dollar sales per convenience store per week for the 13 weeks to 26 March 2016
  • #9 selling chocolate candy in the US single-serve immediate consumption convenience store market, for the 13 weeks to 26 March 2016

So What?

A solid improvement and no mean feat, although the ‘newness’ of Yowie’s offering undoubtedly helped it beat out stalwarts like Snickers and M&Ms – as did the recent festive and Easter seasons. I also note that convenience store sales appear to have declined, although Yowie is only placed in 3.7% of US convenience stores.

What investors need to ask themselves is if today’s announcement materially de-risks the company. In my opinion, it does not. It’s great to see that Yowies continue to sell well, and today’s announcement prevents the addition of a further risk (e.g., if sales were slowing), but that’s all.

Major risks still remain around spending, ongoing litigation, other potential litigation, pending patent approval, and of course, competition. Yowie could also improve its market transparency, with the company often choosing to focus on presenting its sales in ‘retail sales value’ (the cost of Yowies on the store shelf) rather than their actual sales value to Yowie.

As things stand, today’s announcement is a positive development and I continue to believe Yowie is a decent value, albeit a riskier investment.

Want to know our favourite picks for new money today? 

When renowned dividend investing pros like Andrew Page issue buy alerts, it pays to listen. Investors who followed Andrew's recommendation of Australian Pharmaceuticals in early 2015 could've doubled their money in just over a year, turning $15,000 into over $30,000 by the time he recommended they sell and lock in their profits. Chances are you won't want to miss uncovering the names of Andrew's newest share recommendation ,and short list of 3 dividend Best Buys Now Shares.
Simply click here to learn more about these potentially life-changing shares.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Sean O'Neill owns shares of Yowie Group Ltd.. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.